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Introduction: Mutations	 in	 the	angiogenin	 (ANG)	 gene	are	known	 to	be	associated	
with	both	familial	and	sporadic	amyotrophic	lateral	sclerosis	(ALS).	The	majority	of	
disease‐causing	mutations	of	ANG	result	in	loss	of	either	ribonucleolytic	activity,	nu‐
clear translocation activity or both.
Methods: We sequenced ANG	gene	from	a	total	of	136	sporadic	ALS	patients	and	






ulations suggested that the R33W mutation results in partial loss of ribonucleolytic 





evidence from computational and functional analyses support the deleterious effect 
of the novel R33W variant detected in this study.







of	 cases	 are	 sporadic	 with	 no	 family	 history	 (sALS),	 whereas	 the	
remaining	 5%–10%	 is	 familial	 (fALS;	 Renton,	 Chiò,	 &	 Traynor,	
2014);	 however,	 the	 clinical	 features	of	 fALS	and	 sALS	are	 almost	
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indistinguishable.	In	the	past	decades,	more	than	30	genes	involved	
in	 the	 etiology	 of	 the	 disease	 have	 been	 identified	 (Amyotrophic	
Lateral	 Sclerosis	Online	Genetics	 Database,	 ALSoD;	 Abel,	 Powell,	
Andersen,	 &	 Al‐Chalabi,	 2012).	 The	 prevalence	 of	 mutations	 of	
the	two	most	frequently	mutated	genes,	SOD1 and C9orf72 repeat 
expansion	 was	 previously	 reported	 for	 the	 Hungarian	 population	
(Tripolszki	et	al.,	2017).
First	 reported	 in	 2004,	 substantial	 evidence	 has	 accumulated	
for angiogenin	 (ANG)	 involvement	 in	 ALS	 (Greenway	 et	 al.,	 2004;	
Sheng	&	Xu,	2016).	To	date,	approximately	30	different	mutations	






iting	 protein	 translation	 by	 cleaving	 transfer	 RNA	 (tRNA;	 Ivanov,	
Emara,	Villen,	Gygi,	&	Anderson,	2011).	ANG	is	synthesized	with	a	
signal peptide of 24 amino acids that is cleaved to form the mature 
protein	 (Fett	 et	 al.,	 1985;	 Shapiro,	 Riordan,	 &	 Vallee,	 1986).	 The	
mature protein contains three functional sites: a receptor binding 






rite outgrowth during early embryonic development and that it pro‐
tects	against	hypoxia‐induced	motor	neuron	death	(Kishimoto	et	al.,	
2005;	Moroianu	&	Riordan,	1994;	Sebastià	et	al.,	2009).	Mutations	in	
the ANG gene cause loss of either ribonucleolytic activity or nuclear 
translocation	activity	or	both	(Wu	et	al.,	2007).
The aim of this study was to evaluate the contribution of muta‐
tions in ANG,	a	major	ALS	gene,	to	the	pathogenesis	of	the	disease	
in Hungarian patients. The patients positive for SOD1 or C9orf72 
repeat	expansion	 identified	 in	our	previous	study	 (Tripolszki	et	al.,	
2017)	were	not	excluded,	as	there	is	evidence	that	ALS	is	oligogenic	
(van	Blitterswijk	et	al.,	2012).	To	explore	the	underlying	mechanisms	





sequences from various species shows the conservation of the R33 residue
(a) (b)
(c)
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that result in loss of function of the detected R33W mutant pro‐
tein,	computational	simulations,	ribonucleolytic	assays,	and	nuclear	
translocation assays were performed.
2  | PATIENTS AND METHODS
2.1 | Patients
The	 investigated	sporadic	patients	 (n	=	136)	were	 recruited	 from	








according to the Principles of the Declaration of Helsinki.
2.2 | Methods
2.2.1 | Genetic analysis
Genomic	DNA	was	 isolated	 from	 frozen	 blood	 using	DNeasy	Blood	
and	Tissue	kit	(QIAGEN,	Gödöllő,	Hungary).	The	coding	region	and	the	









able	 from	 the	 dbNSFP	 database	 v3.0	 (MetaSVM,	 MetaLR,	 CADD,	
PROVEAN,	 SIFT,	MutationTaster,	MutationAssessor)	were	 used	 (Liu,	
Wu,	Li,	&	Boerwinkle,	2016).	Amino	acid	numbering	of	ANG	is	accord‐
ing	to	the	ALS	Online	Database	(Abel	et	al.,	2012),	which	has	been	used	
in the previous published reports on ANG mutations.














dition of Cl− counter ions and simulations were carried out using the 
SANDER	module	of	 the	AMBER	14	software	package	with	ff14SB	
force	field	(Maier	et	al.,	2015).

















2.2.4 | Graphics and figure preparation




The	 ribonucleolytic	 activity	 of	 the	 wild‐type	 and	 mutant	 ANG	
protein was determined by measuring their activity toward yeast 
tRNA	 (Shapiro	 et	 al.,	 1986).	 The	 30	 μl	 assay	 mixtures	 contained	
0.05–0.4	mg/ml	wild‐type	 or	 R33W	mutant	 ANG	 (14.3	 kDa)	with	
>95%	 purity	 (Novoprotein	 Scientific,	 Summit,	 NJ),	 30	 mM	 4‐(2‐
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were seeded at 5 × 105	cells/ml	onto	an	eight‐well	cell	culture	slide	
(Biologix,	Shandong,	China)	and	incubated	with	1	μg/ml	of	wild‐type	




























serve	 significant	 differences	 in	 allelic	 distributions	 between	 sALS	




One	 of	 the	 patients,	 who	 was	 described	 in	 our	 previous	 study	
(Tripolszki	 et	 al.,	 2017),	 also	 carried	 a	mutation	 in	 the	SOD1 gene 
(V14M).
Clinical report: The other patient with the ANG	M‐24I	mutation	
was	a	79‐year‐old	woman.	Her	symptoms	started	6	months	before	
the	examination	with	progressing	dysphagia	and	dysarthria.	On	ex‐




of lower motor neuron damage were detected with electromyog‐
raphy	 (EMG).	The	revised	ALS	Functional	Rating	Scale	 (ALSFRS‐R)	
was	33	(the	normal	score	is	48).	The	Mini‐Mental	State	Examination	







year‐old	 man	 presenting	 with	 severe	 weakness	 of	 the	 right	 arm	
due	 to	muscle	 atrophy.	 Slight	 bulbar	 and	 pseudobulbar	 weakness	
was	noted,	and	the	muscle	strength	also	diminished	in	his	 left	arm	
without	severe	atrophy	of	the	muscles.	The	lower	extremities	were	
relatively	 strong.	 The	 patient	 could	 walk	 normally.	 Nevertheless,	
fasciculations	were	 seen	 in	 all	 the	muscles	 of	 the	 extremities	 and	
observed together with fibrillations and positive sharp waves on 





was 28 and was comparable with the global impression that the pa‐
tient had no intellectual deficit. The initial disease sign was lower 







predicted R33W to be pathogenic.
3.3.1 | Molecular dynamics simulations
MD	 simulation	 of	 the	 R33W	 variant	 protein	 was	 carried	 out	 to	
model structural and dynamics changes in the functional sites 
compared	 to	 the	 wild‐type	 protein.	 The	 backbone	 root	 mean	
square	deviation	(RMSD)	of	the	R33W	variant	obtained	from	MD	
simulations	 showed	 that,	 although	 the	 fluctuations	 were	 higher	
than	the	wild‐type	during	the	first	15	ns,	it	subsequently	stabilized	
and	converged	as	observed	in	the	wild‐type	ANG	(Figure	S1).	This	
suggested	 that	 the	Arg33	 to	Trp33	mutation	may	not	 affect	 the	
structural stability of the mutant.
3.3.2 | Conformational switching of catalytic 
residue His114 causes loss of ribonucleolytic function 
in the R33W protein
MD	 simulations	 were	 carried	 out	 to	 examine	 whether	 the	 R33W	 
variant	exhibits	a	 loss	of	 ribonucleolytic	activity.	A	100	ns	all‐atom	
simulation of the R33W variant protein revealed that one of the 
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catalytic	 residues,	 His114,	 exhibited	 a	 characteristic	 conformational	
switching	from	its	native	position	during	the	simulations	(Figure	2A).	
As	 established	 in	 our	 previous	 studies	 (Padhi,	 Jayaram,	 &	 Gomes,	
2013;	Padhi,	Vasaikar,	Jayaram,	&	Gomes,	2013;	Padhi	et	al.,	2014),	this	
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100%)	(Figure	3).	The	result	of	this	enzymatic	activity	assay	was	con‐
sistent	with	the	MD	simulation	results.
3.3.3 | Local folding of nuclear localization signal 
abolishes nuclear translocation activity of the 
R33W variant
The nuclear translocation activity of the R33W variant was in‐
vestigated	 from	MD	 simulations.	Our	 100	 ns	 simulation	 of	 R33W	
variant	 showed	 that	 the	 key	 nuclear	 localization	 signal	 residues	
31RRW33 undergo local folding and becomes less accessible to 
solvent	as	compared	to	wild‐type	(Figure	4A).	This	resulted	in	a	re‐
duced	SASA	in	the	R33W	variant	compared	to	the	wild‐type,	which	
retained an open conformation and loosely packed 31RRR33 resi‐
dues	(Figure	4B).	Since	the	31RRR33	residues	are	known	to	play	a	
pivotal	role	in	the	nuclear	translocation	of	ANG,	we	predicted	that	
a	 decrease	 in	 SASA	 due	 to	 the	 local	 folding	 and	 close	 packing	 of	
31RRR33 residues originated due to the replacement of hydrophilic 
Arg33	to	hydrophobic	Trp33	would	probably	lead	to	the	loss	of	nu‐
clear	translocation	activity	in	R33W	variant.	Our	MD	simulated	re‐
sults were verified through nuclear translocation assay performed 
on	 cultured	 HUVEC	 cells.	 Treatment	 with	 wild‐type	 and	 mutant	
R33W protein and subsequent immunofluorescent staining dem‐
onstrated	that	while	wild‐type	ANG	translocated	 into	the	nucleus,	







nucleus was also confirmed by quantification of nuclear/signal in‐
tensity	 (Figure	5b).	Besides	 the	difference	 in	nuclear	 translocation	
activity,	whole	cellular	staining	intensity	was	decreased	in	the	R33W	
ANG‐treated	 samples	 compared	 to	 the	WT	ANG‐treated	 samples	
(Figure	5c),	 suggesting	a	defect	 in	 the	cellular	 recognition	process	
and	 internalization	of	 the	mutant	 protein.	Untreated	HUVEC	 cells	
showed	no	staining	for	ANG	(Figure	S3a).
Clinical	 report:	 The	R33W	variant	was	 carried	by	 a	55‐year‐old	
male patient presented to our clinic with severe distally dominant at‐
rophy of the muscles in the arms with weakness. He noticed the initial 
symptoms	 1	 year	 before	 examination.	 A	 gradually	worsening	 diffi‐
culty of swallowing developed about half year after the initial symp‐
toms. The tongue was atrophic and the articulation was compromised. 
He	lost	25	kg	weight	since	symptom	onset.	On	physical	and	on	EMG	
examinations,	frequent	fasciculations	and	fibrillations	were	observed	




arms were useless. He had been treated for depression in the previous 
2	years.	The	ALSFRS‐R	was	35.	The	MMSE	could	not	be	performed	





patients. The frequency of ANG	mutations	 in	our	Hungarian	 sALS	
cohort	(4/136;	2.9%)	is	higher	than	previously	reported.	According	
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to	previous	studies,	the	frequency	of	ANG mutations in patients with 






was detected in two Hungarian patients in this study. The biological 
function of the signal peptide is not entirely understood; hence it is 
difficult	to	predict	the	effect	of	the	M‐24I	mutation.	Nonetheless,	it	
affects	the	start	codon	(ATG)	of	the	gene,	which	may	influence	the	
correct translation of the protein.






The	 V103I	 mutation	 affects	 an	 amino	 acid	 that	 is	 conserved	 in	
mammals	 and	 it	 was	 first	 detected	 in	 an	 ALS	 cohort	 of	 Chinese	





showing its open conformation and loose 
packing of 31RRR33	nuclear	localization	
signal residues as compared to the closed 
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origin	(Zou	et	al.,	2011).	According	to	previously	reported	molecular	
simulation	results	of	the	V103I	variant	structure,	a	hydrogen	bond	







The	R33W	missense	 variant,	 located	 in	 the	 nuclear	 translocation	
signal	of	the	mature	protein,	has	not	been	identified	in	ALS	patients	
before. To understand the role of the mutation in disease manifes‐
tation,	 a	 computational	 and	 functional	 analysis	of	 the	R33W	mu‐
tant	was	performed.	Our	MD	simulations	showed	that	 the	R33W	
mutation results in partial loss of ribonucleolytic activity and im‐
paired nuclear translocation activity. The ribonucleolytic assay and 
nuclear	 translocation	 assay	of	 the	R33W	ANG	protein	 confirmed	
the	MD	results.	According	to	the	ribonucleolytic	activity	assay,	the	
R33W	mutant	 protein	 retained	 57.4%	 of	 catalytic	 activity	 of	 the	
wild‐type	 protein.	 Previous	 studies	 described	 that	 the	 reported	
disease‐causing	 ANG	 mutations—except	 variant	 R121C—show	 a	





compromised. Our nuclear translocation assay showed that the al‐
teration	of	Arg33	 to	Trp33	 in	ANG	 significantly	 reduced	 its	 entry	
into	the	nucleus.	Amino	acids	29IMRRRGL35 are part of the nuclear 
localization	signal	and	are	involved	in	nuclear	translocation	of	ANG.	
The arginine residues 31RRR33 are critical in governing the nuclear 
translocation	of	ANG:	R33	 is	 essential	 and	 residues	 31RR32 modu‐
late	 the	 process.	Moroianu	 and	Riordan	 (1994)	 described	 that	 the	












1994).	Alterations	 in	 the	 structure	of	ANG	and	dynamics	 result	 in	
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loss	of	 ribonucleolytic	activity	and/or	nuclear	 translocation	ability,	
which	may	lead	to	ALS.
For	 the	R33W	variant,	 a	 strong	 correlation	 between	 the	 com‐
putational simulation predictions and functional analyses was ob‐
served.	 The	 evidence	 from	 clinical,	 computational,	 and	 functional	
analyses support the deleterious effect of the R33W variant de‐
tected in this study. Our findings also confirm the relevance of ANG 
mutations	 in	ALS	and	points	out	the	variability	among	populations	
of different ethnic origin. It underscores a substantial role of ANG 
variants	in	Hungarian	ALS	patients,	and	suggests	the	importance	of	
further large cohort studies.
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